I am a board-certified medical oncologist whose practice is devoted to the care of patients with melanoma. I work closely with a multidisciplinary team of Memorial Sloan Kettering melanoma surgeons, radiation oncologists, pathologists, nurses, and patient advocates to deliver the best possible care for our patients and their families.
Significant treatment advances have been made for patients with melanoma, but I believe we can do even better. My research focuses on improving the immunotherapeutic and targeted therapeutic strategies for the treatment of melanoma. I am honored to have received research awards from the American Society of Clinical Oncology and the Society for Immunotherapy of Cancer. I am also excited about having recently published a handbook on all aspects of oncology care, called Pocket Oncology.
I strongly believe in the importance of creating a close, trusting relationship with each patient as we work together for the best treatment plan possible.
- Clinical Expertise: Melanoma; Clinical Trials of New Immunotherapeutic and Targeted Therapeutic Agents
- Languages Spoken: English
- Education: MD, New York University School of Medicine
- Residencies: Brigham and Women's Hospital/Harvard Medical School
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Pocket Oncology. Drilon AE, Postow MA eds. Philadelphia: Lippincott Williams & Wilkins; 2014.
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Michael A. Postow
- A Phase II Study of LEE011 plus MEK162 in Patients with NRAS-Mutant Melanoma
- A Phase II Study of LGX818 plus MEK162, Followed by Another Targeted Drug If Needed, in Patients with Locally Advanced or Metastatic Melanoma with a BRAF Mutation
- A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230)) in Patients with Advanced Uveal Melanoma